References

¹Centers for Disease Control and Prevention (CDC). CDC State Heart Disease and Stroke Prevention Program. More information available at www.cdc.gov/dhdsp/state_program/index.htm; accessed October 31, 2006.

²More information available at http://hin.nhlbi.nih.gov/educs/awardees.htm; accessed October 31, 2006.

³More information available at www.cdc.gov/reach2010/; accessed October 31, 2006.

⁴National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine 333(24):1581–1597, 1995.

⁵National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 106:3143–3421, 2002.

⁶Grundy, S.M., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110:227–239, 2004. More information available at http://circ.ahajournals.org/content/vol110/issue2/index.shtml#NCEP_REPORT; accessed October 31, 2006.

⁷Grundy, S.M. Cholesterol-lowering trials: A historical perspective. In Grundy, S.M., ed. Cholesterol Lowering Therapy: Evaluation of Clinical Trial Evidence. New York, NY: Marcel Dekker Inc., 1–329, 2000.

⁸Stroke prevention in atrial fibrillation study. Final results. Circulation 84:527–539, 1991.

⁹Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet 343:687–691, 1994.

¹⁰Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 348:633–638, 1996.

¹¹Aguilar, M.I., and Hart, R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews, (3), 2005.

¹²Rothwell, P.M., et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK, from 1981 to 2004 (Oxford Vascular Study). Lancet 363:1925–1933, 2004.

¹³Woo, D., et al. Genetic and environmental risk factors for intracerebral hemorrhage. Stroke 33:1190–1196, 2002.

¹⁴Broderick, J., et al. Lobar hemorrhage in the elderly. The undiminishing importance of hypertension. Stroke 24:49–51, 1993.

¹⁵Broderick, J.P., et al. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. New England Journal of Medicine 326:733–736, 1992.

¹⁶Wolf, P.A., et al. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22:983–988, 1991.

¹⁷Dulli, D.A., et al. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 22(2):118–123, 2003.

¹⁸Fields, L.E., et al. The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension 44(4):398–404, 2004.

¹⁹Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health (NIH) Publication No. 04-5230. Bethesda, MD: National High Blood Pressure Education Program (NHBPEP), NIH, National Heart, Lung, and Blood Institute (NHLBI), September 2004.

²⁰Svetkey, L.P., et al. Effect of the Dietary Approaches to Stop Hypertension Diet and reduced sodium intake on blood pressure control. Journal of Clinical Hypertension 6(7):373–381, 2004.

²¹More information available at http://hin.nhlbi.nih.gov/mission/; accessed October 31, 2006.

²²Chobanian, A.V., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252, 2003.

²³NIH. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. NIH Publication No. 98-4083. Bethesda, MD: NHLBI, 1998.

²⁴Brown, C.D., et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obesity Research 8:605–619, 2000.

²⁵Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360(9326):7–22, 2000.

²⁶Shepherd, J., et al. PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet 360(9346):1623–1630, 2002.

²⁷ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Journal of the American Medical Association 288:2998–3007, 2002.

²⁸Balcazar, H., et al. A comprehensive promotora outreach program to promote heart-healthy behaviors among Hispanics. Health Promotion Practice 7(1):68–77, 2006.

²⁹More information available at www.nhlbi.nih.gov/health/prof/heart/latino/lat_mnl.htm; accessed October 31, 2006.

³⁰Unpublished program implementation documents.

³¹More information available at www.nhlbi.nih.gov/health/prof/heart/other/aian_manual/amer_indian.htm; accessed October 31, 2006.

³²More information available at www.nhlbi.nih.gov/health/prof/heart/other/aian_manual/alaska_native.htm; accessed October 31, 2006.

³³More information available at www.nhlbi.nih.gov/health/prof/heart/latino/lat_mnl.htm; accessed October 31, 2006.

³⁴More information available at http://ice.iqsolutions.com/ninds/strokepubs.asp; accessed October 31, 2006.

³⁵CDC. WISEWOMAN (Well Integrated Screening and Evaluation for Women Across the Nation). More information available at www.cdc.gov/wisewoman/; accessed October 31, 2006.

³⁶More information available at www.hearttruth.gov; accessed October 31, 2006.

³⁷U.S. Department of Health and Human Services (HHS). A Public Health Action Plan to Prevent Heart Disease and Stroke. Atlanta, GA: HHS, CDC, 2003. More information available at www.cdc.gov/cvh/Action_Plan/index.htm; accessed October 31, 2006.

³⁸Alberts, M.J., et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. Journal of the American Medical Association 283(23):3102–3109, 2000.

³⁹Alberts, M.J., et al. Recommendations for comprehensive stroke centers: A consensus statement from the Brain Attack Coalition. Stroke 36(7):1597–1616, 2005. More information available at http://stroke.ahajournals.org/cgi/reprint/01.STR.0000170622.07210.b4v1; accessed October 31, 2006.

⁴⁰Hemphill, J.C., et al. Is neurointensive care really optional for comprehensive stroke care? [Letter.] Stroke 36(11):2344–2345, 2005.

⁴¹American Heart Association. Get With The Guidelines. More information available at http://americanheart.org/presenter.jhtml?identifier=1165; accessed October 31, 2006.

⁴²Koffman, D.M., et al. Successful Business Strategies to Prevent Heart Disease and Stroke Toolkit. Atlanta, GA: HHS, CDC, National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, 2005. More information available at http://www.cdc.gov/dhdsp/library/toolkit/pdfs/toolkit.pdf; accessed October 31, 2006.

⁴³More information available at www.nhlbi.nih.gov/actintime/; accessed October 31, 2006.

⁴⁴The States include Arkansas, Kansas, and Washington. CDC. State Cardiovascular Health Examination Survey. More information available at www.cdc.gov/dhdsp/state_program/examination_survey.htm; accessed October 31, 2006.

⁴⁵More information available at www.cdc.gov/cvh; accessed October 31, 2006.

⁴⁶Ford, E.S., et al. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. Journal of the American Medical Association 287:356–359, 2002.

⁴⁷Ford, E.S., et al. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27(10):2444–2449, 2004. More information available at http://care.diabetesjournals.org/cgi/content/full/27/10/2444; accessed October 31, 2006.

⁴⁸Grundy, S.M., et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/NHLBI scientific statement. Circulation 112:2735–2752, 2005.

⁴⁹More information available at http://wecan.nhlbi.nih.gov; accessed October 31, 2006.

⁵⁰Sorof, J., and Daniels, S. Obesity hypertension in children: A problem of epidemic proportions. Hypertension 40:441–447, 2002.

⁵¹NHBPEP. Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. NIH Publication No. 05-5267. Bethesda, MD: NHBPEP, NIH, NHLBI, May 2005. More information available at www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.htm; accessed October 31, 2006.

⁵²Sorof, J.M., et al. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 111:61–66, 2003.

⁵³Hanevold, C., et al. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: A collaborative study of the International Pediatric Hypertension Association. Pediatrics 113:328–333, 2004.

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®.

<<  Previous—Objectives and Subobjectives   |   Table of Contents  |  Next—Related Objectives From Other Focus Areas  >>